FDA Approves Ipilimumab for Advanced Melanoma - Medscape
Mar 25, 2011 · Ipilimumab "is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment." The pivotal study of …
FDA Approves Nivolumab + Ipilimumab for Certain CRC Patients
3 days ago · Median PFS with nivolumab + ipilimumab vs nivolumab monotherapy was not reached vs 39.3 months, respectively (HR, 0.62), and the overall response rates were 71% …
Advances in Systemic Treatments for Melanoma Highlighted
Feb 7, 2025 · According to the final results of the trial, 4-year RFS was 64.2% in the nivolumab plus ipilimumab group, 31.4% in the nivolumab alone group, and 15% in the placebo group, …
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
Jan 23, 2024 · First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy. This site is …
How New Research Is Redefining Melanoma Treatment - Medscape
Jan 23, 2025 · Long-term data from the CheckMate 067 trial confirmed the superiority of nivolumab combined with ipilimumab, as well as nivolumab monotherapy, compared with …
Improved Safety Profile With 'Flip Dose' Nivo/Ipi Regimen
Jul 5, 2019 · This was a randomized, phase 3 trial of either standard-dose ipilimumab and nivolumab, which were given as four induction doses over 12 weeks, followed by maintenance …
ASCO 2024: Updates on Clinical Trials in Gynecologic Cancers
Jun 24, 2024 · Nivolumab plus ipilimumab is a widely available combination that we believe is showing important activity for people with this relatively rare, very aggressive histology called …
Improved Survival With Ipilimumab in Patients With ... - Medscape
Ipilimumab, a novel immunotherapy that relieves T cells of an inhibitory signal, given in combination with a human leukocyte antigen (HLA)-restricted peptide vaccine, or alone, …
Ipilimumab Improves Survival in Advanced Melanoma - Medscape
Jun 6, 2010 · Ipilimumab is a targeted T-cell antibody, a new class of drugs, said Dr. O'Day. It is directed against an antigen on the surface of T cells. The antigen, cytotoxic T-lymphocyte …
Vemurafenib and Ipilimumab to Be Tried Together - Medscape
Ipilimumab is an immune-boosting therapy with a slow onset of effect and a low rate of objective responses, though the complete responses seen are generally durable. It can result in durable ...